Macular Cystoid Edema Induced by Nab-Paclitaxel

Edema Macular Cistóide Secundário ao Nab-Paclitaxel

Sara ALVES PEREIRA1, Carolina VALE1, Jorge MOREIRA1, Filipa SAMPAIO1
Acta Med Port 2021 34(AOP) • https://doi.org/10.20344/amp.13421

ABSTRACT
A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis.

Keywords: Albumins/adverse effects; Albumin-Bound Paclitaxel/adverse effects; Macular Edema/chemically induced; Paclitaxel/adverse effects; Pancreatic Neoplasms/drug therapy

INTRODUCTION
Taxanes are a group of chemotherapeutic agents that inhibit cell division by causing stabilization of cellular microtubules. Agents in this group include paclitaxel (a natural compound extracted from the yew tree), docetaxel (a semisynthetic analog) and nanoparticle albumin–bound (nab)-paclitaxel (better bioavailability and tolerability than paclitaxel).1,2 Taxanes are approved for the treatment of breast, ovarian and lung cancer, but they are also used off-label in several other malignancies (e.g. endometrial, gastroesophageal, prostate, among others).1 Nab-paclitaxel combined with gemcitabine has been recently advocated as a standard treatment option for metastatic pancreatic cancer.2,3 Common associated side effects of taxane therapy include neuropathy and hypersensitivity reactions.4,5 Macular edema is a very rare side effect and its etiopathology is still misunderstood.6

CLINICAL CASE
A 61-year-old male presented with a history of bilateral and progressive vision loss in the previous month. The patient had a diagnosis of metastatic pancreatic cancer diagnosed five months before and had been treated with gemcitabine and albumin protein bound paclitaxel (nab-paclitaxel). He was also taking a proton-pump inhibitor, gabapentin and tapentadol for chronic pain. The remaining past medical history, including ophthalmic history, was irrelevant.

Upon examination, the patient’s visual acuity was 4/20 and 2/20 in the right and left eye, respectively. The anterior segment examination was unremarkable, but fundoscopy showed an altered foveal reflex present bilaterally. The spectral-domain optical coherence tomography (SD-OCT) revealed a thickened retina with multiple intraretinal hyporeflective cystic spaces, mainly affecting the outer plexiform layer, suggestive of cystoid macular edema. A small foveal area of subretinal fluid coexisted in the left eye. The central retinal thickness (CRT) was 671 and 582 µm, in the right and left eye, respectively. A small area of retinal edema was present in the right eye (Fig. 1). No other lesions or changes were evident on fundoscopy or optical coherence tomography (OCT).

Fluorescein angiography was not performed given the patient’s general health status and the high clinical suspicion of taxane-related maculopathy. Follow-up was performed with OCT only.
Nab-paclitaxel was discontinued, and chemotherapy was altered to gemcitabine + capecitabine. The patient was also treated with topical nonsteroidal anti-inflammatory drops of nepafenac, for one month, to hasten recovery. Six weeks after drug discontinuation, best corrected visual acuities improved to 12/20 and 6/20 in the right and left eye, respectively. The SD-OCT showed a marked reduction of the intraretinal fluid, with only small cystic spaces remaining, and a decreased retinal thickness (CRT of 371 and 435 µm in the right and left eye, respectively) (Fig. 2). Three months after stopping treatment, visual acuity improved to 20/20 and 16/20 and the SD-OCT showed complete resolution of the cystoid macular edema, with CRT of 288 µm in the right eye and 280 µm in the left eye, respectively (Fig. 3). The patient’s malignancy was stable under the alternative chemotherapy regimen, with no signs of toxicity or systemic side effects.

DISCUSSION

Macular edema is caused by fluid accumulation in the retina’s extracellular space, leading to abnormal macular thickening. Macular edema can be classified as diffuse or cystoid (when there is evidence of fluid accumulation in the macula in cyst-like spaces).7

Taxanes are a class of microtubule stabilizing agents used as chemotherapeutic agents in several malignancies. These agents are known to cause, in very rare instances, a macular edema that is silent on fluorescein angiography (without fluorescein leakage from retinal vessels).8,9 The differential diagnosis of cystoid macular edema without (or minimal) fluorescein leakage includes Goldmann-Favre syndrome, niacin maculopathy, juvenile X-linked retinoschisis and some subtypes of retinitis pigmentosa.10 Taxane-related macular edema is usually bilateral and the time interval from exposure to clinical presentation can range from a few months to about 2.5 years.8,11

The pathophysiology of this taxane-related maculopathy is still unclear. Some authors proposed a mechanism of toxicity to the retinal pigment epithelium (RPE) cells, while others have suggested the role of direct toxicity to the Muller cells, causing swelling. Other possible explanations could be the leakage of molecules smaller than fluorescein (or at a slow leaking rate) not detected by conventional fluorescein angiography.10,12,13

Drug discontinuation is the appropriate management of this condition and macular edema is usually reversible upon drug discontinuation.8 Visual acuity frequently improves with resolution of macular edema, but the length of treatment and duration of edema can influence visual outcomes. Adjuvant treatment in these cases remains controversial. Use of topical (and sub-tenon or intravitreal) corticosteroids, non-steroidal anti-inflammatory drugs and carbonic anhydrase inhibitors have been described with little or no efficacy.10,12

Taxanes may be associated, in very rare cases, with the development of reversible macular edema. Clinicians, especially oncologists and ophthalmologists, should be aware of this potential side effect in order to better diagnose and treat this condition.

AUTHORS CONTRIBUTION

SAP: Draft of the paper.
CV: Analysis and interpretation of the materials.
JM, FS: Critical review and approval of the final version of the paper.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the 2013 Helsinki Declaration of the World Medical Association.

DATA CONFIDENTIALITY

The authors declare that they followed the protocols in use at their working center regarding patients’ data publication.

PATIENT CONSENT

Obtained.

COMPETING INTERESTS

The authors have declared that no competing interests exist.

FUNDING SOURCES

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES


Figure 1 – OCT revealing severe cystoid macular edema of the right and left eye at presentation
Figure 2 – OCT (right and left eye) six weeks after drug withdrawal with marked improvement of edema
Figure 3 – Normal OCT (right and left eye) three months after drug discontinuation